TIGRIS and EUPHRATES eventually join and provide new evidence: a narrative review of the polymyxin B hemoperfusion
Authors' conclusion
These results support the targeted use of PMX-HP in a biomarker-defined subgroup
Study context
- Population
- Septic shock with intermediate endotoxin activity (EAA 0.60–0.89) and MODS > 9 (TIGRIS trial)evaluable, TIGRIS
- Participants
- 151 participants
- Comparison
- Polymyxin B hemoperfusion vs control
- Outcome
- Survival benefit (posterior probability, Bayesian design)
- Follow-up
- 28 days
Main finding
As reported in the abstract
28-day mortality (TIGRIS)
Adjusted OR for death
0.67
95.3% posterior probability of 28-day survival benefit
Adjusted relative risk
6.4%
28-day mortality (TIGRIS)
Further findings
| Outcome | Adjusted OR |
|---|---|
| Mortality (TIGRIS) · 90 daysARR 17.4% | 0.54 |
- Mortality (TIGRIS) — Posterior probability of benefit
- > 99%
- Mortality (TIGRIS) — NNT
- 8.1
Original publication
TIGRIS and EUPHRATES eventually join and provide new evidence: a narrative review of the polymyxin B hemoperfusion. J Intensive Care. Published 25 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →